JP2005532276A - 免疫化組成物およびアミロイド前駆体タンパク質のβ−セクレターゼ開裂部位に対する免疫応答を誘発する方法 - Google Patents

免疫化組成物およびアミロイド前駆体タンパク質のβ−セクレターゼ開裂部位に対する免疫応答を誘発する方法 Download PDF

Info

Publication number
JP2005532276A
JP2005532276A JP2003574670A JP2003574670A JP2005532276A JP 2005532276 A JP2005532276 A JP 2005532276A JP 2003574670 A JP2003574670 A JP 2003574670A JP 2003574670 A JP2003574670 A JP 2003574670A JP 2005532276 A JP2005532276 A JP 2005532276A
Authority
JP
Japan
Prior art keywords
aβpp
cleavage site
secretase cleavage
antigen
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003574670A
Other languages
English (en)
Japanese (ja)
Inventor
ソロモン，ベカ
Original Assignee
ラモト アト テル−アヴィヴ ユニバーシティ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラモト アト テル−アヴィヴ ユニバーシティ リミテッド filed Critical ラモト アト テル−アヴィヴ ユニバーシティ リミテッド
Publication of JP2005532276A publication Critical patent/JP2005532276A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2003574670A 2002-03-05 2003-03-04 免疫化組成物およびアミロイド前駆体タンパク質のβ−セクレターゼ開裂部位に対する免疫応答を誘発する方法 Pending JP2005532276A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36134402P 2002-03-05 2002-03-05
PCT/US2003/006388 WO2003076455A2 (en) 2002-03-05 2003-03-04 Immunizing composition and method for inducing an immune response against the ss-secretase cleavage site of amyloid precursor protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010114047A Division JP2010248197A (ja) 2002-03-05 2010-05-18 免疫化組成物およびアミロイド前駆体タンパク質のβ−セクレターゼ切断部位に対する免疫応答を誘発するための方法

Publications (1)

Publication Number Publication Date
JP2005532276A true JP2005532276A (ja) 2005-10-27

Family

ID=27805031

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2003574670A Pending JP2005532276A (ja) 2002-03-05 2003-03-04 免疫化組成物およびアミロイド前駆体タンパク質のβ−セクレターゼ開裂部位に対する免疫応答を誘発する方法
JP2010114047A Pending JP2010248197A (ja) 2002-03-05 2010-05-18 免疫化組成物およびアミロイド前駆体タンパク質のβ−セクレターゼ切断部位に対する免疫応答を誘発するための方法
JP2013107244A Expired - Fee Related JP5717210B2 (ja) 2002-03-05 2013-05-21 免疫化組成物およびアミロイド前駆体タンパク質のβ−セクレターゼ切断部位に対する免疫応答を誘発するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2010114047A Pending JP2010248197A (ja) 2002-03-05 2010-05-18 免疫化組成物およびアミロイド前駆体タンパク質のβ−セクレターゼ切断部位に対する免疫応答を誘発するための方法
JP2013107244A Expired - Fee Related JP5717210B2 (ja) 2002-03-05 2013-05-21 免疫化組成物およびアミロイド前駆体タンパク質のβ−セクレターゼ切断部位に対する免疫応答を誘発するための方法

Country Status (8)

Country Link
US (3) US7494655B2 (https=)
EP (2) EP2292247A3 (https=)
JP (3) JP2005532276A (https=)
AU (1) AU2003225636A1 (https=)
CA (1) CA2477675C (https=)
ES (1) ES2392247T3 (https=)
IL (3) IL163812A0 (https=)
WO (1) WO2003076455A2 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009523738A (ja) * 2006-01-20 2009-06-25 スターファーマ・プロプライエタリー・リミテッド 修飾高分子
JP2012509672A (ja) * 2008-11-24 2012-04-26 ラモト アト テル−アヴィヴ ユニバーシティ リミテッド 繊維状バクテリオファージを使用してパーキンソン病を処置するための方法
US8193248B2 (en) 2006-03-22 2012-06-05 Starpharma Pty Limited Contraceptive composition
US8258259B2 (en) 2005-10-25 2012-09-04 Starpharma Pty Limited Macromolecular compounds having controlled stoichiometry
US8420067B2 (en) 2006-08-11 2013-04-16 Starpharma Pty Ltd Targeted polylysine dendrimer therapeutic agent
US8568753B2 (en) 2005-10-18 2013-10-29 Starpharma Pty Limited Delivery system

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1398019A1 (de) 2002-09-13 2004-03-17 Cognis France S.A. Verfahren zum Schutz und zur Modulation von Dermal Epidermal Junctions
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2005033278A2 (en) * 2003-09-30 2005-04-14 Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus iscom
MX2007005053A (es) * 2004-10-28 2007-06-19 Eisai R&D Man Co Ltd Metodo para evaluar la enfermedad de alzheimer y reactivo de diagnostico.
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
AU2007275258A1 (en) * 2006-07-21 2008-01-24 Ramot At Tel Aviv University Ltd. Use of a phage displaying a peptide from an adhesion protein for treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates
US8492341B2 (en) 2006-11-28 2013-07-23 Alzyme Pty Ltd. Amyloid-β binding peptides
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
CN101809153B (zh) 2007-09-27 2014-01-01 日本烟草产业株式会社 参与疱疹病毒的潜伏感染的因子及其利用
GB0720912D0 (en) 2007-10-25 2007-12-05 Univ Cardiff Monoclonal Anitbody for APP
KR101397554B1 (ko) * 2007-11-09 2014-05-21 재단법인서울대학교산학협력재단 치매(알츠하이머 병)의 진단, 예방, 치료제 및 이들의스크리닝 방법
US8921523B2 (en) 2007-12-11 2014-12-30 Glaxo Group Limited Humanized anti-beta-amyloid antibodies
WO2009124119A2 (en) * 2008-04-01 2009-10-08 The Trustes of Columbia University in the City of New York Phosphodiesterase inhibitors and uses thereof
WO2009155538A1 (en) * 2008-06-20 2009-12-23 Merck & Co., Inc. Compositions and methods of depleting amyloid-beta peptides from cerebrospinal fluid to treat alzheimer's disease
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
JP2012513464A (ja) 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
WO2011031720A1 (en) * 2009-09-11 2011-03-17 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Bispecific nanobodies as a therapeutic for alzheimer's disease
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
WO2015199247A1 (ja) * 2014-06-27 2015-12-30 日本たばこ産業株式会社 気分障害を診断、治療又は予防する方法
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN106349334A (zh) * 2015-07-15 2017-01-25 韩震 一种多肽化合物及其制备方法与应用
CN108431046A (zh) 2015-12-28 2018-08-21 日本烟草产业株式会社 诊断、治疗或预防心境障碍的方法
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229490A (en) * 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
JP2002502802A (ja) * 1997-12-02 2002-01-29 ニューララブ リミテッド アミロイド形成疾患の予防および処置

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376861A (en) 1976-06-23 1983-03-15 The Dow Chemical Company Method for preparing 2-alkenyl-2-oxazolines
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4600535A (en) 1982-02-12 1986-07-15 The Dow Chemical Company Cyclic peptides
US4517122A (en) 1982-02-12 1985-05-14 The Dow Chemical Company Cyclic peptides
US4558120A (en) 1983-01-07 1985-12-10 The Dow Chemical Company Dense star polymer
US4568737A (en) 1983-01-07 1986-02-04 The Dow Chemical Company Dense star polymers and dendrimers
US4507466A (en) 1983-01-07 1985-03-26 The Dow Chemical Corporation Dense star polymers having core, core branches, terminal groups
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4515920A (en) 1984-04-30 1985-05-07 The Rockefeller University Synthesis of peptides and proteins
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
US4587329A (en) 1984-08-17 1986-05-06 The Dow Chemical Company Dense star polymers having two dimensional molecular diameter
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4599400A (en) 1984-12-18 1986-07-08 The Dow Chemical Company Star/comb-branched polyamide
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
ES2217250T3 (es) * 1990-06-15 2004-11-01 Scios Inc. Mamifero transgenico, no humano que muestra la patologia de formacion amiloides de la enfermedad de alzheimer.
US5222982A (en) 1991-02-11 1993-06-29 Ommaya Ayub K Spinal fluid driven artificial organ
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
WO1993022343A1 (en) 1992-05-01 1993-11-11 The Rockfeller University Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom
US5716614A (en) 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
JPH11507538A (ja) 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ
US6221645B1 (en) 1995-06-07 2001-04-24 Elan Pharmaceuticals, Inc. β-secretase antibody
US5744346A (en) 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
US5719867A (en) 1995-06-30 1998-02-17 Scientific-Atlanta, Inc. Plural telephony channel baseband signal demodulator for a broadband communications system
WO1998021589A1 (en) 1996-11-15 1998-05-22 The Trustees Of The University Of Pennsylvania Screening for modulators of amyloid processing
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
US6703015B1 (en) * 1999-09-03 2004-03-09 Ramot At Tel-Aviv University Ltd. Filamentous bacteriophage displaying an β-amyloid epitope
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6313268B1 (en) 1998-10-16 2001-11-06 Vivian Y. H. Hook Secretases related to Alzheimer's dementia
GB2364059B (en) 1999-02-10 2004-01-14 Elan Pharm Inc Beta-Secretase enzyme compositions and methods
WO2001014579A2 (en) * 1999-08-26 2001-03-01 Vion Pharmaceuticals, Inc. Compositions and methods for delivery of an agent using attenuated salmonella containing phage
US20040013647A1 (en) * 1999-09-03 2004-01-22 Ramot At Tel-Aviv University Ltd. Methods and compositions for treating a plaque-forming disease
AU784568B2 (en) * 1999-09-03 2006-05-04 Ramot At Tel-Aviv University Ltd Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
US20020052311A1 (en) * 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
WO2001053457A2 (en) * 2000-01-21 2001-07-26 University Of Connecticut Health Center Vaccines against neurodegenerative disorders
WO2003000719A2 (en) * 2001-06-20 2003-01-03 Ramot At Tel Aviv University Ltd. Multiple antigenic peptide displaying multiple copies of an epitope of plaque-forming polypeptide and methods of using same
AU2003226356A1 (en) * 2002-04-12 2003-10-27 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
GB0720912D0 (en) * 2007-10-25 2007-12-05 Univ Cardiff Monoclonal Anitbody for APP

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229490A (en) * 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
JP2002502802A (ja) * 1997-12-02 2002-01-29 ニューララブ リミテッド アミロイド形成疾患の予防および処置

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VASSAR R, BENNETT BD, BABU-KHAN S, KAHN S, MENDIAZ EA, DENIS P, TEPLOW DB, ROSS S, AMARANTE P, LOELO: "Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic prote", SCIENCE, vol. 286(5440), JPN7009001837, 1999, pages 735 - 741, ISSN: 0001295094 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8568753B2 (en) 2005-10-18 2013-10-29 Starpharma Pty Limited Delivery system
US8258259B2 (en) 2005-10-25 2012-09-04 Starpharma Pty Limited Macromolecular compounds having controlled stoichiometry
US8586705B2 (en) 2005-10-25 2013-11-19 Starpharma Pty Limited Macromolecular compounds having controlled stoichiometry
JP2009523738A (ja) * 2006-01-20 2009-06-25 スターファーマ・プロプライエタリー・リミテッド 修飾高分子
US8337823B2 (en) 2006-01-20 2012-12-25 Starpharma Pty Limited Modified macromolecule
US8703116B2 (en) 2006-01-20 2014-04-22 Starpharma Pty Limited Modified macromolecule
US8193248B2 (en) 2006-03-22 2012-06-05 Starpharma Pty Limited Contraceptive composition
US8420067B2 (en) 2006-08-11 2013-04-16 Starpharma Pty Ltd Targeted polylysine dendrimer therapeutic agent
JP2012509672A (ja) * 2008-11-24 2012-04-26 ラモト アト テル−アヴィヴ ユニバーシティ リミテッド 繊維状バクテリオファージを使用してパーキンソン病を処置するための方法

Also Published As

Publication number Publication date
IL212752A (en) 2014-01-30
IL163812A (en) 2011-06-30
EP2292247A3 (en) 2011-10-05
EP1480666B1 (en) 2012-06-13
JP2013181034A (ja) 2013-09-12
JP5717210B2 (ja) 2015-05-13
US20070172484A1 (en) 2007-07-26
ES2392247T3 (es) 2012-12-07
WO2003076455A2 (en) 2003-09-18
EP1480666A4 (en) 2006-06-07
WO2003076455A3 (en) 2004-04-08
AU2003225636A1 (en) 2003-09-22
US7494655B2 (en) 2009-02-24
CA2477675A1 (en) 2003-09-18
US20060034855A1 (en) 2006-02-16
AU2003225636A8 (en) 2003-09-22
US20110070249A1 (en) 2011-03-24
EP2292247A2 (en) 2011-03-09
EP1480666A2 (en) 2004-12-01
IL212752A0 (en) 2011-07-31
US8613928B2 (en) 2013-12-24
JP2010248197A (ja) 2010-11-04
CA2477675C (en) 2013-05-21
IL163812A0 (en) 2005-12-18
US7854931B2 (en) 2010-12-21

Similar Documents

Publication Publication Date Title
JP5717210B2 (ja) 免疫化組成物およびアミロイド前駆体タンパク質のβ−セクレターゼ切断部位に対する免疫応答を誘発するための方法
AU2013305848B2 (en) Compositions and methods related to diseases associated with deposits of amyloid, Tau, and alpha-synuclein
ES2549070T3 (es) Prevención y tratamiento de una enfermedad sinucleinopática
ES2714692T3 (es) Tratamiento de tauopatías
CN101420983B (zh) 包含超分子抗原构建体的组合物和方法
JP2003534351A (ja) アミロイドβ及びアミロイド沈着物に対する免疫応答誘導のための、アミロイドβと相同的な、合成の、免疫原性だが非アミロイド原性ペプチド
JP2009519915A (ja) 治療ワクチン
HRP20050670A2 (en) Active immunization to generate antibodies to soluble a-beta
ES2727407T3 (es) Prevención y tratamiento de enfermedad sinucleinopática y amiloidogénica
EP1397380B1 (en) Multiple antigenic peptide displaying multiple copies of an epitope of a plaque-forming polypeptide and methods of using same
TWI254050B (en) Synthetic peptide composition as immunogens for prevention of urinary tract infection
US20060276400A1 (en) Modulation of cholesteryl ester transfer protein (CETP) activity
CN121001737A (zh) Tau和β淀粉样肽免疫原组合物及相关方法
DK2465533T3 (en) Methods and compositions comprising supramolecular constructs
CN103539840B (zh) 表皮生长因子受体模拟表位肽及其应用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090428

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090727

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090925

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091026

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100119

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100506

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100518

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100616